Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China

References

• World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Available from: https://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. Accessed September 7, 2020.
   Google Scholar
• CDC. Antibiotic resistance threats in the United States; 2019. Available from: https://www.cdc.gov/drugresistance/biggest-threats.html. Accessed September 7, 2020.
   Google Scholar
• Suay-García B, Pérez-Gracia MT. Present and future of carbapenem-resistant Enterobacterales (CRE) infections. Antibiotics. 2019;8(3):122. doi:10.3390/antibiotics8030122
   Web of Science ®Google Scholar
• Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S521–S528. doi:10.1093/cid/ciz824
   PubMed Web of Science ®Google Scholar
• Zhang R, Liu L, Zhou H, et al. Nationwide surveillance of clinical carbapenem-resistant Enterobacterales (CRE) strains in China. EBioMedicine. 2017;19:98–106. doi:10.1016/j.ebiom.2017.04.032
   PubMed Web of Science ®Google Scholar
• Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacterales infections. Emerg Infect Dis. 2014;20(7):1170–1175. doi:10.3201/eid2007.121004
   PubMed Web of Science ®Google Scholar
• Karampatakis T, Antachopoulos C, Iosifidis E, et al. Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in Greece. Future Microbiol. 2016;6(11):809–823. doi:10.2217/fmb-2016-0042
   Web of Science ®Google Scholar
• Goodman KE, Simner PJ, Tamma PD, et al. Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacterales (CRE). Expert Rev Anti Infect Ther. 2016;14(1):95–108. doi:10.1586/14787210.2016.1106940
   PubMed Web of Science ®Google Scholar
• Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev. 2015;28(2):337–418. doi:10.1128/CMR.00117-14
   PubMed Web of Science ®Google Scholar
• Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapenemases in Klebsiella pneumoniae and other Enterobacterales: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682–707. doi:10.1128/CMR.05035-11
   PubMed Web of Science ®Google Scholar
• Sader HS, Mendes RE, Pfaller MA, et al. Antimicrobial activities of aztreonam–avibactam and comparator agents against contemporary (2016) clinical Enterobacterales isolates. Antimicrob Agents Chemother. 2018;62(1):e01856–17. doi:10.1128/AAC.01856-17
   Web of Science ®Google Scholar
• Sader HS, Castanheira M, Shortridge D, et al. Antimicrobial activity of ceftazidime–avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. Medical centers, 2013 to 2016. Antimicrob Agents Chemother. 2017;61(11):e01045–17. doi:10.1128/AAC.01045-17
   Web of Science ®Google Scholar
• Falcone M, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR gram-negative infections. J Antimicrob Chemother. 2016;71(10):2713–2722. doi:10.1093/jac/dkw239
   PubMed Web of Science ®Google Scholar
• Abboud MI, Damblon C, Brem J, et al. Interaction of avibactam with class B metallo-β-lactamases. Antimicrob Agents Chemother. 2016;60(10):5655–5662. doi:10.1128/AAC.00897-1610
   PubMed Web of Science ®Google Scholar
• Bush K. Game changers: new β-lactamase inhibitor combinations targeting antibiotic resistance in Gram-negative bacteria. ACS Infect Dis. 2018;4(2):84–87. doi:10.1021/acsinfecdis.7b00243
   Web of Science ®Google Scholar
• Li H, Zhang J, Liu Y, et al. Molecular characteristics of carbapenemase-producing Enterobacterales in China from 2008 to 2011: predominance of KPC-2 enzyme. Diagn Microbiol Infect Dis. 2014;78(1):63–65. doi:10.1016/j.diagmicrobio.2013.10.002
   PubMed Web of Science ®Google Scholar
• Zhang R, Chan EW, Zhou H, et al. Prevalence and genetic characteristics of carbapenem- resistant Enterobacterales strains in China. Lancet Infect Dis. 2017;17(3):256–257. doi:10.1016/S1473-3099(17)30072-5
   Web of Science ®Google Scholar
• Bush K, Bradford PA. Epidemiology of β-lactamase-producing pathogens. Clin Microbiol Rev. 2020;33(2):e00047–19. doi:10.1128/CMR.00047-19
   PubMed Web of Science ®Google Scholar
• Hsu LY, Apisarnthanarak A, Khan E, et al. Carbapenem-resistant Acinetobacter baumannii and Enterobacterales in South and Southeast Asia. Clin Microbiol Rev. 2017;30(1):1–22. doi:10.1128/CMR.masthead.30-11
   PubMed Web of Science ®Google Scholar
• Han R, Shi Q, Wu S, et al. Dissemination of carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacterales isolated from adult and children patients in China. Front Cell Infect Microbiol. 2020;10:314. doi:10.3389/fcimb.2020.00314
   Web of Science ®Google Scholar
• Wang Q, Wang X, Wang J, et al. Phenotypic and genotypic characterization of carbapenem-resistant Enterobacterales: data from a longitudinal large-scale CRE study in China (2012–2016). Clin Infect Dis. 2018;67(S2):S196–205. doi:10.1093/cid/ciy660
   Web of Science ®Google Scholar
• Zhang Y, Wang Q, Yin Y, et al. Epidemiology of carbapenem-resistant Enterobacterales infections: report from the China CRE network. Antimicrob Agents Chemother. 2018;62(2):e01882–17. doi:10.1128/AAC.01882-17
   PubMed Web of Science ®Google Scholar
• Wei J, Zou C, Wang D, et al. Genetic diversity and in vitro activity of ceftazidime/avibactam and aztreonam/avibactam against imipenem-resistant Enterobacterales isolates in Southwest China: a single-centre study. J Glob Antimicrob Resist. 2020;22:448–451. doi:10.1016/j.jgar.2020.04.023
   Web of Science ®Google Scholar
• Zou C, Wei J, Shan B, et al. In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against carbapenem-resistant Enterobacterales isolates collected from three secondary hospitals in Southwest China between 2018 and 2019. Infect Drug Resist. 2020;13:3563–3568. doi:10.2147/IDR.S273989
   Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne, PA: CLSI; 2020.
   Google Scholar
• Tian X, Sun S, Jia X, et al. Epidemiology of and risk factors for infection with extended-spectrum β-lactamase-producing carbapenem-resistant Enterobacterales: results of a double case–control study. Infect Drug Resist. 2018;11:1339–1346. doi:10.2147/IDR.S173456
   PubMed Web of Science ®Google Scholar
• Niu S, Wei J, Zou C, et al. In vitro selection of aztreonam/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumonia. J Antimicrob Chemother. 2020;75(3):559–565. doi:10.1093/jac/dkz468
   Web of Science ®Google Scholar
• Tian D, Pan F, Wang C, et al. Resistance phenotype and clinical molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae among pediatric patients in Shanghai. Infect Drug Resist. 2018;11:1935–1943. doi:10.2147/IDR.S175584
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhu Z, Jia W, et al. In vitro activity of aztreonam–avibactam against metallo-β- lactamase-producing Enterobacterales-A multicenter study in China. Int J Infect Dis. 2020;97:11–18. doi:10.1016/j.ijid.2020.05.075
   Web of Science ®Google Scholar
• Rodríguez-Bano J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacterales. Clin Microbiol Rev. 2018;31(2):e00079–17. doi:10.1128/CMR.00079-17
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacterales (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–734. doi:10.1016/S1473-3099(17)30228-1
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943–950. doi:10.1093/cid/cis588
   PubMed Web of Science ®Google Scholar